Viewing Study NCT05987332

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 9:49 PM
Ignite Modification Date: 2026-06-02 @ 9:22 PM
Study NCT ID: NCT05987332
Status: RECRUITING
Last Update Posted: 2025-11-07
First Post: 2023-07-12
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
Sponsor: IDEAYA Biosciences
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Metastatic Uveal Melanoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None IDE196 View
None Darovasertib View
None Protein Kinase C View
None Metastatic Uveal Melanoma View
None Melanoma View
None Ocular Oncology View
None Ophthalmology View
None Crizotinib View
None Ocular melanoma View